NBTX - Nanobiotix logo

Nanobiotix

NBTX

Nanobiotix S.A. develops cancer treatment therapies utilizing hafnium oxide nanoparticles, particularly NBTXR3, targeting various cancers including soft tissue sarcoma and lung cancer. The company collaborates with Lian Oncology for commercialization in Asia.

⚕️ Healthcare NASDAQ Listed 2020 € EUR
$1,000 invested 5 years ago →$2,629today

Score Overview

1 Year
Score
Net Growth-338.09%
Net TrendShrank
Net Income Consistency—
Rev Growth-43.14%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.0
Net Growth-123.33%
Net Trend40%
Net Income Consistency—
Rev Growth6x
Rev Trend60%
Revenue Consistency—
All Time
Score
Net Growth-212.51%
Net Trend33%
Net Income Consistency
Rev Growth7x
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Nanobiotix has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. NBTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 31.50—
1 Year2025-09-29
$ 18.0274.81%
5 Years2021-09-29
$ 11.98162.94%
All Time2020-12-11
$ 16.9885.51%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in EUR

Year
TTM€ 16M-€ 104M€ 110M
2025€ 29M-€ 23M€ 52M
2024-€ 7M-€ 68M€ 49M
2023€ 36M-€ 39M€ 75M
2022€ 4M-€ 57M€ 41M
2021€ 2M-€ 47M€ 84M
IPO2020€ 2M-€ 33M€ 119M
NBTX - Nanobiotix logo

Nanobiotix fundamental performance

Between 2020 and 2025, revenue grew from € 2M to € 29M and net income went from -€ 33M to -€ 23M. Revenue increased in 3 of those 5 years; net income in 2.

Nanobiotix currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Explore NBTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies